Sfoglia per Autore
Prospective evaluation of candidate snps of vegf/vegfr pathway in metastatic colorectal cancer patients treated with first-line folfiri plus bevacizumab (BV).
2012-01-01 Cremolini, Chiara; Loupakis, F; Yang, D; Salvatore, L; Zhang, W; Wakatsuky, T; Schirripa, M; Lonardi, S; Antoniotti, C; Aprile, G; Masi, G; Graziano, F; Ruzzo, A; Lucchesi, S; Maus, M; Bocci, Guido; Falcone, Alfredo; Lenz, H. J.
FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutant metastatic colorectal cancer patients.
2012-01-01 Salvatore, L; Loupakis, F; Cremolini, Chiara; Schirripa, M; Masi, G; Antoniotti, C; Fornaro, L; Sensi, E; Lupi, C; Bergamo, F; Lonardi, S; Zagonel, V; Fontanini, Gabriella; Falcone, Alfredo
Folfoxiri plus Bevacizumab as first-line treatment of BRAF mutant metastatic colorectal cancer patients.
2012-01-01 Salvatore, L; Loupakis, F; Cremolini, Chiara; Schirripa, M; Masi, G; Antoniotti, C; Fornaro, L; Sensi, E; Lupi, C; Bergamo, F; Lonardi, S; Zagonel, V; Fontanini, Gabriella; Falcone, Alfredo
A multicenter, randomized phase III study of second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients who progressed to a first-line treatment containing bv: results from the bebyp trial by the Gruppo Oncologico Nord Ovest (GONO).
2012-01-01 Salvatore, L; Masi, G; Loupakis, F; Cremolini, Chiara; Schirripa, M; Fornaro, L; Antoniotti, C; Vivaldi, C; Granetto, C; Fea, E; Antonuzzo, L; Giommoni, E; Boni, C; Banzi, M; Chiara, S; Sonaglio, C; Allegrini, G; Marcucci, L; Valsuani, C; Greco, F; Safina, V; Boni, L; Falcone, Alfredo
Prospective study of EGFR intron 1 CA tandem repeats to predict factor benefit from cetuximab and irinotecan.
2012-01-01 Antoniotti, C; Loupakis, F; Cremolini, Chiara; Zhang, W; Yang, D; Wakatsuki, T; Schirripa, M; Salvatore, L; Ricci, V; Graziano, F; Masi, G; Ruzzo, A; Labonte, M. J.; Ning, Y; EL KHOUEIRY, R; Falcone, Alfredo; Lenz, H. J.
Folfoxiri plus bevacizumab as first-line treatment of BRAF mutant metastatic colorectal cancer patients.
2012-01-01 Bergamo, F; Loupakis, F; Salvatore, L; Cremolini, Chiara; Schirripa, M; Masi, G; Antoniotti, C; Fornaro, L; Sensi, E; Lupi, C; Lonardi, S; Zagonel, V; Fontanini, Gabriella; Falcone, Alfredo
Prospective evaluation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI plus bevacizumab (BV).
2012-01-01 Cremolini, Chiara; Loupakis, F; Yang, D; Salvatore, L; Zhang, W; Wakatsuki, T; Schirripa, M; Lonardi, S; Antoniotti, C; Aprile, G; Masi, G; Graziano, F; Ruzzo, A; Lucchesi, S; Ronzoni, M; HERBERT MAUS, M. K.; Bocci, Guido; Tonini, G; Falcone, Alfredo; Lenz, H. J.
Prospective evaluation of candidate snps of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC) patients treated with first-line folfiri plus bevacizumab (BV).
2012-01-01 Cremolini, Chiara; Loupakis, F; Yang, D; Salvatore, L; Zhang, W; Wakatsuki, T; Schirripa, M; Lonardi, S; Antoniotti, C; Casagrande, M; Aprile, G; Masi, G; Graziano, F; Ruzzo, A; Lucchesi, S; Ronzoni, M; Maus, M. K. H.; Bocci, Guido; Tonini, G; Lenz, H. J.; Falcone, Alfredo
Prospective study of EGFR intron 1 ca tandem repeats as predictive factor of benefit from cetuximab and irinotecan.
2012-01-01 Antoniotti, C; Loupakis, F; Cremolini, Chiara; Zhang, W; Yang, D; Wakatsuki, T; Schirripa, M; Salvatore, L; Ricci, V; Graziano, F; Masi, G; Ruzzo, A; Lutrino, S. E.; Labonte, M. J.; Ning, Y; EL KHOUEIRY, R; Falcone, Alfredo; Lenz, H. J.
KSR1 gene polymorphism in MCRC patients treated with first-line folfiri and bevacizumab.
2012-01-01 Schirripa, M; Loupakis, F; Cremolini, Chiara; Yang, D; Labonte, M; Zhang, W; Salvatore, L; Wakatsuki, T; EL KHOUEIRY, R; Antoniotti, C; Aprile, G; Ferrari, L; Maus, M. K. H.; Lucchesi, S; Allegrini, G; DE VITA, F; Zhang, H; Giamas, G; Stebbing, J; Falcone, Alfredo; Lenz, H. J.
KSR1 gene polymorphism in mCRC patients treated with first-line FOLFIRI and bevacizumab.
2012-01-01 Schirripa, M; Loupakis, F; Cremolini, Chiara; Yang, D; Labonte, M. J.; Zhang, W; Salvatore, L; Wakatsuki, T; EL KHOUEIRY, R; Antoniotti, C; Aprile, G; HERBERT MAUS, M. K.; Lucchesi, S; Allegrini, G; DE VITA, F; Zhang, H; Giamas, G; Stebbing, J; Falcone, Alfredo; Lenz, H. J.
Ksr1 gene polymorphism in mcrc patients treated with first-line folfiri and bevacizumab.
2012-01-01 Schirripa, M; Loupalis, F; Cremolini, Chiara; Dongyun, Y; Labonte, M. J.; Zhang, W; Salvatore, L; Wakatsuky, T; Antoniotti, C; Aprile, G; Lucchesi, S; Giamas, G; Justin, S; Falcone, Alfredo; Lenz, H. J.
Primary tumor location is a major independent prognostic factor for mcrc patients.
2012-01-01 Loupakis, F; Yang, D; Feng, S; Cremolini, Chiara; Zhang, W; Antoniotti, C; Langer, C; Hurwitz, H; Saltz, L; Falcone, Alfredo; Lenz, H. J.
Primary side of origin affects the outcome of mCRC patients treated with first-line FOLFIRI plus bevacizumab independently of BRAF status and mucinous histology.
2012-01-01 Loupakis, F.; Yang, D.; Zhang, W.; Cremolini, Chiara; Wakatsuki, T.; Salvatore, L.; Antoniotti, C.; Aprile, G.; Schirripa, M.; Ricci, V.; Lucchesi, S.; Masi, G.; Herbert Maus, M. K.; Lonardi, S.; Ning, Y.; El Khoueiry, R.; Falcone, Alfredo; Lenz, H. J.
Upfront chemotherapy regimens in unresectable disease: one, two, or three cytotoxics?
2012-01-01 Cremolini, Chiara; Loupakis, Fotios; Antoniotti, C.; Salvatore, L.; Schirripa, M.; Fornaro, L.; Masi, G.; Falcone, Alfredo
FDG-PET/CT (PET) in the early prediction of benefit from first-line chemotherapy plus bevacizumab (bev) in metastatic colorectal cancer (mCRC).
2013-01-01 Salvatore, L; Loupakis, F; Cremolini, Chiara; Schirripa, M; Antoniotti, C; Marmorino, F; Zoratto, F; Bergamo, F; Brunetti, I. M.; Pfanner, E; Masi, G; Genovesi, D; Filidei, I; Giorgetti, A; Falcone, Alfredo
Prospective analysis of the early modulation of plasma amphiregulin (AR) during treatment with cetuximab and irinotecan in irinotecan-refractory metastatic colorectal cancer (mCRC) patients (pts).
2013-01-01 Cremolini, Chiara; Loupakis, F; Antoniotti, C; Fioravanti, A; Orlandi, P; Salvatore, L; Canu, B; Schirripa, M; Masi, G; DI DESIDERO, T; Marmorino, F; Bergamo, F; Zoratto, F; Bocci, Guido; Falcone, Alfredo
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Traslational analyses from the phase III BEBYP trial.
2013-01-01 Antoniotti, C; Loupakis, F; Cremolini, Chiara; Bocci, Guido; Fioravanti, A; Masi, G; Salvatore, L; Marmorino, F; Orlandi, P; Schirripa, M; Bergamo, F; Zoratto, F; DI DESIDERO, T; Canu, B; Danesi, Romano; Falcone, Alfredo
Prospective Analysis of the Early Modulation of Plasma Amphiregulin During Treatment with Cetuximab and Irinotecan in Metastatic Colorectal Cancer Patients
2013-01-01 Antoniotti, Carlotta; Cremolini, Chiara; Loupakis, Fotios; Fioravanti, Anna; Orlandi, Paola; Salvatore, Lisa; Canu, Bastianina; Schirripa, Marta; Masi, Gianluca; Di Desidero, Teresa; Marmorino, Federica; Bergamo, Francesca; Zoratto, Federica; Bocci, Guido; Falcone, Alfredo
Metronomic capecitabine (cape) and cyclophosphamide (CTX) for refractory metastatic colorectal cancer (mCRC): Results of a phase II trial.
2013-01-01 Marmorino, F; Cremolini, Chiara; Loupakis, F; Salvatore, L; Schirripa, M; Antoniotti, C; DI DESIDERO, T; Canu, B; Orlandi, P; Fioravanti, A; Masi, G; Bocci, Guido; Falcone, Alfredo
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Prospective evaluation of candidate snps of vegf/vegfr pathway in metastatic colorectal cancer patients treated with first-line folfiri plus bevacizumab (BV). | 1-gen-2012 | Cremolini, Chiara; Loupakis, F; Yang, D; Salvatore, L; Zhang, W; Wakatsuky, T; Schirripa, M; Lonardi, S; Antoniotti, C; Aprile, G; Masi, G; Graziano, F; Ruzzo, A; Lucchesi, S; Maus, M; Bocci, Guido; Falcone, Alfredo; Lenz, H. J. | |
| FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutant metastatic colorectal cancer patients. | 1-gen-2012 | Salvatore, L; Loupakis, F; Cremolini, Chiara; Schirripa, M; Masi, G; Antoniotti, C; Fornaro, L; Sensi, E; Lupi, C; Bergamo, F; Lonardi, S; Zagonel, V; Fontanini, Gabriella; Falcone, Alfredo | |
| Folfoxiri plus Bevacizumab as first-line treatment of BRAF mutant metastatic colorectal cancer patients. | 1-gen-2012 | Salvatore, L; Loupakis, F; Cremolini, Chiara; Schirripa, M; Masi, G; Antoniotti, C; Fornaro, L; Sensi, E; Lupi, C; Bergamo, F; Lonardi, S; Zagonel, V; Fontanini, Gabriella; Falcone, Alfredo | |
| A multicenter, randomized phase III study of second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients who progressed to a first-line treatment containing bv: results from the bebyp trial by the Gruppo Oncologico Nord Ovest (GONO). | 1-gen-2012 | Salvatore, L; Masi, G; Loupakis, F; Cremolini, Chiara; Schirripa, M; Fornaro, L; Antoniotti, C; Vivaldi, C; Granetto, C; Fea, E; Antonuzzo, L; Giommoni, E; Boni, C; Banzi, M; Chiara, S; Sonaglio, C; Allegrini, G; Marcucci, L; Valsuani, C; Greco, F; Safina, V; Boni, L; Falcone, Alfredo | |
| Prospective study of EGFR intron 1 CA tandem repeats to predict factor benefit from cetuximab and irinotecan. | 1-gen-2012 | Antoniotti, C; Loupakis, F; Cremolini, Chiara; Zhang, W; Yang, D; Wakatsuki, T; Schirripa, M; Salvatore, L; Ricci, V; Graziano, F; Masi, G; Ruzzo, A; Labonte, M. J.; Ning, Y; EL KHOUEIRY, R; Falcone, Alfredo; Lenz, H. J. | |
| Folfoxiri plus bevacizumab as first-line treatment of BRAF mutant metastatic colorectal cancer patients. | 1-gen-2012 | Bergamo, F; Loupakis, F; Salvatore, L; Cremolini, Chiara; Schirripa, M; Masi, G; Antoniotti, C; Fornaro, L; Sensi, E; Lupi, C; Lonardi, S; Zagonel, V; Fontanini, Gabriella; Falcone, Alfredo | |
| Prospective evaluation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI plus bevacizumab (BV). | 1-gen-2012 | Cremolini, Chiara; Loupakis, F; Yang, D; Salvatore, L; Zhang, W; Wakatsuki, T; Schirripa, M; Lonardi, S; Antoniotti, C; Aprile, G; Masi, G; Graziano, F; Ruzzo, A; Lucchesi, S; Ronzoni, M; HERBERT MAUS, M. K.; Bocci, Guido; Tonini, G; Falcone, Alfredo; Lenz, H. J. | |
| Prospective evaluation of candidate snps of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC) patients treated with first-line folfiri plus bevacizumab (BV). | 1-gen-2012 | Cremolini, Chiara; Loupakis, F; Yang, D; Salvatore, L; Zhang, W; Wakatsuki, T; Schirripa, M; Lonardi, S; Antoniotti, C; Casagrande, M; Aprile, G; Masi, G; Graziano, F; Ruzzo, A; Lucchesi, S; Ronzoni, M; Maus, M. K. H.; Bocci, Guido; Tonini, G; Lenz, H. J.; Falcone, Alfredo | |
| Prospective study of EGFR intron 1 ca tandem repeats as predictive factor of benefit from cetuximab and irinotecan. | 1-gen-2012 | Antoniotti, C; Loupakis, F; Cremolini, Chiara; Zhang, W; Yang, D; Wakatsuki, T; Schirripa, M; Salvatore, L; Ricci, V; Graziano, F; Masi, G; Ruzzo, A; Lutrino, S. E.; Labonte, M. J.; Ning, Y; EL KHOUEIRY, R; Falcone, Alfredo; Lenz, H. J. | |
| KSR1 gene polymorphism in MCRC patients treated with first-line folfiri and bevacizumab. | 1-gen-2012 | Schirripa, M; Loupakis, F; Cremolini, Chiara; Yang, D; Labonte, M; Zhang, W; Salvatore, L; Wakatsuki, T; EL KHOUEIRY, R; Antoniotti, C; Aprile, G; Ferrari, L; Maus, M. K. H.; Lucchesi, S; Allegrini, G; DE VITA, F; Zhang, H; Giamas, G; Stebbing, J; Falcone, Alfredo; Lenz, H. J. | |
| KSR1 gene polymorphism in mCRC patients treated with first-line FOLFIRI and bevacizumab. | 1-gen-2012 | Schirripa, M; Loupakis, F; Cremolini, Chiara; Yang, D; Labonte, M. J.; Zhang, W; Salvatore, L; Wakatsuki, T; EL KHOUEIRY, R; Antoniotti, C; Aprile, G; HERBERT MAUS, M. K.; Lucchesi, S; Allegrini, G; DE VITA, F; Zhang, H; Giamas, G; Stebbing, J; Falcone, Alfredo; Lenz, H. J. | |
| Ksr1 gene polymorphism in mcrc patients treated with first-line folfiri and bevacizumab. | 1-gen-2012 | Schirripa, M; Loupalis, F; Cremolini, Chiara; Dongyun, Y; Labonte, M. J.; Zhang, W; Salvatore, L; Wakatsuky, T; Antoniotti, C; Aprile, G; Lucchesi, S; Giamas, G; Justin, S; Falcone, Alfredo; Lenz, H. J. | |
| Primary tumor location is a major independent prognostic factor for mcrc patients. | 1-gen-2012 | Loupakis, F; Yang, D; Feng, S; Cremolini, Chiara; Zhang, W; Antoniotti, C; Langer, C; Hurwitz, H; Saltz, L; Falcone, Alfredo; Lenz, H. J. | |
| Primary side of origin affects the outcome of mCRC patients treated with first-line FOLFIRI plus bevacizumab independently of BRAF status and mucinous histology. | 1-gen-2012 | Loupakis, F.; Yang, D.; Zhang, W.; Cremolini, Chiara; Wakatsuki, T.; Salvatore, L.; Antoniotti, C.; Aprile, G.; Schirripa, M.; Ricci, V.; Lucchesi, S.; Masi, G.; Herbert Maus, M. K.; Lonardi, S.; Ning, Y.; El Khoueiry, R.; Falcone, Alfredo; Lenz, H. J. | |
| Upfront chemotherapy regimens in unresectable disease: one, two, or three cytotoxics? | 1-gen-2012 | Cremolini, Chiara; Loupakis, Fotios; Antoniotti, C.; Salvatore, L.; Schirripa, M.; Fornaro, L.; Masi, G.; Falcone, Alfredo | |
| FDG-PET/CT (PET) in the early prediction of benefit from first-line chemotherapy plus bevacizumab (bev) in metastatic colorectal cancer (mCRC). | 1-gen-2013 | Salvatore, L; Loupakis, F; Cremolini, Chiara; Schirripa, M; Antoniotti, C; Marmorino, F; Zoratto, F; Bergamo, F; Brunetti, I. M.; Pfanner, E; Masi, G; Genovesi, D; Filidei, I; Giorgetti, A; Falcone, Alfredo | |
| Prospective analysis of the early modulation of plasma amphiregulin (AR) during treatment with cetuximab and irinotecan in irinotecan-refractory metastatic colorectal cancer (mCRC) patients (pts). | 1-gen-2013 | Cremolini, Chiara; Loupakis, F; Antoniotti, C; Fioravanti, A; Orlandi, P; Salvatore, L; Canu, B; Schirripa, M; Masi, G; DI DESIDERO, T; Marmorino, F; Bergamo, F; Zoratto, F; Bocci, Guido; Falcone, Alfredo | |
| Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Traslational analyses from the phase III BEBYP trial. | 1-gen-2013 | Antoniotti, C; Loupakis, F; Cremolini, Chiara; Bocci, Guido; Fioravanti, A; Masi, G; Salvatore, L; Marmorino, F; Orlandi, P; Schirripa, M; Bergamo, F; Zoratto, F; DI DESIDERO, T; Canu, B; Danesi, Romano; Falcone, Alfredo | |
| Prospective Analysis of the Early Modulation of Plasma Amphiregulin During Treatment with Cetuximab and Irinotecan in Metastatic Colorectal Cancer Patients | 1-gen-2013 | Antoniotti, Carlotta; Cremolini, Chiara; Loupakis, Fotios; Fioravanti, Anna; Orlandi, Paola; Salvatore, Lisa; Canu, Bastianina; Schirripa, Marta; Masi, Gianluca; Di Desidero, Teresa; Marmorino, Federica; Bergamo, Francesca; Zoratto, Federica; Bocci, Guido; Falcone, Alfredo | |
| Metronomic capecitabine (cape) and cyclophosphamide (CTX) for refractory metastatic colorectal cancer (mCRC): Results of a phase II trial. | 1-gen-2013 | Marmorino, F; Cremolini, Chiara; Loupakis, F; Salvatore, L; Schirripa, M; Antoniotti, C; DI DESIDERO, T; Canu, B; Orlandi, P; Fioravanti, A; Masi, G; Bocci, Guido; Falcone, Alfredo |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile